A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male Volunteers

Key facts

Sponsor

Gilead Sciences

Principal Investigator

Peter Hodsman, MD

Nucleus Network Ltd

Intervention

GS-9411(drug)

Enrollment

15 enrolled

Eligibility

18-45 years · MALE

Timeline

2009 – 2009

Study locations (1)

• Nucleus Network, Ltd., Melbourne, Victoria, Australia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Cystic fibrosis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT04530383
  Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function
  University of Kansas Medical Center
• RECRUITINGPHASE2NCT07450547
  Phase 2 Study to Assess the Safety and Efficacy of ANG003
  Anagram Therapeutics, Inc.
• RECRUITINGPHASE1NCT07437105
  Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
  Vertex Pharmaceuticals Incorporated
• RECRUITINGNANCT07436351
  ACT With CF Self-Help Toolkit
  Thomas Jefferson University
• RECRUITINGNCT07369414
  Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at Home
  Research Center Borstel
• RECRUITINGNANCT07314229
  Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor
  University Hospital, Lille
• RECRUITINGNCT07083557
  Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
  Bettina Mittendorfer
• RECRUITINGNCT07505797
  ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)
  iSono Health, Inc.

See all trials for Cystic fibrosis →